Accrual experience of national cancer institute cooperative group phase III trials activated from 2000 to 2007

Journal of Clinical Oncology

Volumn 28, Issue 35, 2010, Pages 5197-5201

  Korn, Edward L ^a   Freidlin, Boris ^a   Mooney, Margaret ^a   Abrams, Jeffrey S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; CANCER THERAPY; CLINICAL PROTOCOL; HUMAN; NATIONAL HEALTH ORGANIZATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PATIENT SELECTION; UNITED STATES;

EID: 79951898822     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.5382     Document Type: Article

References (16)

1. Zuckerman B, Corrigan J: The role of NCI-sponsored research in ASCO Clinical Cancer Advances 2005-2008. J Clin Oncol 28:470s, 2010 (suppl; abstr 6094)
2. Korn EL, Dorey FJ: Applications of crude incidence curves. Stat Med 11:813-829, 1992
3. Cheng S, Dietrich M, Finnigan S, et al: A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. J Clin Oncol 27:325s, 2009 (suppl; abstr CRA6509)
4. Institute of Medicine: A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press, 2010, p 143
5. Editorial: Faltering cancer trials. New York Times, April 24, 2010 (a version of this editorial appeared on p WK11 of the New York edition on April, 25, 2010). http://www.nytimes.com/2010/04/25/opinion/25sun1.html
6. Young RC: Cancer clinical trials: A chronic but curable crisis. N Engl J Med 363:306-309, 2010
7. Stewart DJ, Whitney SN, Kurzrock R: Equipoise lost: Ethics, costs, and the regulation of cancer research. J Clin Oncol 28:2925-2935, 2010
8. Loehrer PJ, Powell ME, Cardenes HR, et al: A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 26:214s, 2008 (suppl; abstr 4506)
9. Winer E, Gralow J, Diller L, et al: Clinical cancer advances 2008: Major research advances in cancer treatment, prevention, and screening - A report from the American Society of Clinical Oncology. J Clin Oncol 27:812-826, 2009
10. Schroen AT, Petroni GR, Wang H, et al: Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials 7:312-321, 2010
11. Cancer Therapy Evaluation Program (CTEP): CTEP-Sponsored Cooperative Group Phase III trials: Early Stopping Guidelines for Slow Accruing Trials. http://ctep.cancer.gov/protocoldevelopment/docs/slow-accrual.pdf
12. Cancer Therapy Evaluation Program (CTEP): Development of Early Stopping Guidelines for Slow Accruing Trials. http://ctep.cancer.gov/protocoldevelopment/ docs/slow-accrual-guidelines-dev.pdf
13. Cancer Trials Support Unit (CTSU). https://www.ctsu.org/public/
14. Engelberg Center for Health Care Reform at Brookings: 2009 Conference on Clinical Cancer Research Event Summary. http://www.brookings.edu/~/media/Files/ events/2009/0914-clinical-cancer-research/Event%20Summary.pdf
15. Wagner TH, Murray C, Goldberg J, et al: Costs and benefits of the National Cancer Institute Central Institutional Review Board. J Clin Oncol 28:662-666, 2010
16. Operational Efficiency Working Group: Report of the Operational Efficiency Working Group of the Clinical Trials and Translational Research Advisory Committee - Compressing the Timeline for Cancer Clinical Trial Activation, March 2010. http://ccct.cancer.gov/files/OEWG-Report.pdf